- RBR ubiquitin ligases are a mechanistically hybrid class of E3 enzymes that combine features of both RING‑type and HECT‑type ubiquitin ligases. The acronym RBR refers to their tripartite architecture: a RING1 domain, a BRcat (benign catalytic) domain, and a RING2 domain. This arrangement enables RBR ligases to first bind an E2 ubiquitin‑conjugating enzyme through the RING1 domain, and then transfer ubiquitin to a catalytic cysteine within the RING2 domain, forming a thioester intermediate. This two‑step mechanism mirrors HECT‑type catalysis, making RBR ligases a unique mechanistic bridge between the two major E3 families.
- The best‑known RBR ligases include Parkin, HHARI and HOIP. Parkin plays a central role in mitochondrial quality control, particularly in mitophagy, where it ubiquitinates outer‑mitochondrial‑membrane proteins to mark damaged mitochondria for autophagic removal. Mutations in Parkin are strongly associated with early‑onset Parkinson’s disease, highlighting the importance of RBR ligases in neuronal homeostasis. HHARI participates in protein‑quality control and cytosolic stress responses, while HOIP is the catalytic core of the LUBAC complex, responsible for assembling M1‑linked linear ubiquitin chains that activate NF‑κB signalling. Through HOIP, RBR ligases directly influence inflammation, immunity and cell‑survival pathways.
- Mechanistically, RBR ligases operate through a RING–HECT hybrid mechanism. The RING1 domain binds the E2~Ub conjugate, positioning ubiquitin for transfer. Instead of directly facilitating substrate ubiquitination, the BRcat–RING2 module receives ubiquitin onto a catalytic cysteine, forming a thioester intermediate. This intermediate allows RBR ligases to dictate ubiquitin‑chain architecture, including the assembly of M1‑linked chains by HOIP or K6/K11/K63‑linked chains by Parkin depending on cellular context. Because RBR ligases directly catalyse chain formation, their activity is tightly regulated through autoinhibition, phosphorylation, conformational changes and co‑factor binding.
- RBR ligases are increasingly recognised for their roles in human disease. Parkin dysfunction contributes to neurodegeneration, mitochondrial stress and impaired mitophagy. HOIP dysregulation affects immune signalling and inflammatory disorders, while mutations in HHARI and related RBR ligases are linked to developmental abnormalities and protein‑homeostasis defects. Their hybrid catalytic mechanism makes RBR ligases attractive therapeutic targets, with ongoing research exploring small molecules that modulate their activation, conformational state or substrate specificity.
- Overall, RBR ubiquitin ligases represent a mechanistically distinct and biologically essential class of E3 enzymes. Their hybrid RING–HECT mechanism allows precise control over ubiquitin‑chain formation, enabling them to regulate mitochondrial quality control, immune signalling, protein homeostasis and cellular stress responses. Understanding RBR ligases provides deep insight into ubiquitin‑mediated regulation and the molecular basis of neurodegeneration, inflammation and cellular quality‑control pathways.
2 thoughts on “RBR Ubiquitin Ligase”